-

Avvio Medical Announces New CPT Code for Its Breakthrough Kidney Stone Treatment Technology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a company dedicated to revolutionizing the treatment of urinary stones, is excited to announce that the American Medical Association (AMA) has officially published the early release of a new Category III CPT code for Avvio’s novel kidney stone treatment system.

Effective January 1, 2026, CPT code 0991T will be used by healthcare providers and facilities nationwide to report procedures utilizing Avvio Medical’s innovative technology. The new code, which reflects the final nomenclature approved by the AMA, marks a significant milestone in Avvio’s journey to expand patient access, improve care, and streamline reimbursement for its groundbreaking approach.

“The introduction of a dedicated CPT code for our technology demonstrates the clinical importance of our ureteral stone solution,” said Paul Molloy, CEO, Avvio Medical. “This achievement will help ensure that physicians and health systems can more easily offer our therapy to patients while benefiting from clear and accurate billing processes.”

Avvio worked with expert reimbursement strategy consultants Jeffrey Dann, M.D., and PRIA Healthcare to support the code application process and overall market access planning.

The announcement was made public as part of the AMA’s official Category III CPT Code Early Release, available here.

What This Means

  • CPT 0991T will take effect January 1, 2026.
  • The new code reflects important progress toward bringing Avvio’s technology to patients and providers.
  • This development highlights Avvio’s commitment to advancing access and innovation in kidney stone care.

About the Enhanced Lithotripsy System (ELS)

The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.

About Avvio Medical

Avvio Medical is a privately held company which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of urinary stones. The company’s initial technology is designed to offer patients and healthcare professionals a fast, minimally invasive solution for treating urinary stone disease in various clinical or outpatient settings, eliminating the routine need for anesthesia or X-ray imaging.

For more information, visit http://www.avviomedical.com/

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

Industry:

Avvio Medical, Inc.

Release Versions
English

Contacts

Paul Molloy
Chief Executive Officer
Avvio Medical, Inc.
Email: paul.molloy@avviomed.com
Tel: (415) 887-2037

More News From Avvio Medical, Inc.

Avvio Medical Receives FDA Breakthrough Device Designation for the Avvio Enhanced Lithotripsy System (ELS)

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company developing next-generation kidney stone treatment technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to the Avvio Enhanced Lithotripsy System (ELS). The designation highlights the system’s potential to improve outcomes, reduce complications, and expand access to minimally invasive, anesthesia-sparing kidney stone care for mill...

Avvio Medical’s Microbubble Technology Reduces Complications and Shows Promise for Enhancing Laser Lithotripsy: AEROLITH Trial Results Published in The Journal of Urology

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical Inc. today announced the publication of its AEROLITH randomized clinical trial in The Journal of Urology. Study highlights were presented at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. The AEROLITH study evaluated the safety and effectiveness of Acoustic Enhancer Microbubble Cavitation (AEMC) when used with ureteroscopic laser lithotripsy (URS-LL) to treat kidney and ureteral stones. Study highlights include:...

Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness

SAN FRANCISCO--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio’s compliance with international standards for medical device quality management systems and reflects the company’s unwaveri...
Back to Newsroom